FIELD: medicine.
SUBSTANCE: present invention relates to biotechnology and medicine, in particular, to methods for treating or preventing multiple sclerosis (MS) in a patient, as well as applications of autologous cytotoxic T cells (CTLs) for producing a medicinal product for treating or preventing multiple sclerosis. Described methods and applications relate to the use of autologous CTLs expressing a T cell receptor specifically binding to the EBV peptide presented on class I MHC, wherein at least 7% of the CTLs express IFNγ.
EFFECT: invention provides a possibility of expanding the range of products for treating such an autoimmune disease as multiple sclerosis.
34 cl, 2 tbl, 2 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOTHERAPY METHODS | 2017 |
|
RU2756276C2 |
| METHODS FOR TREATMENT OF AUTOIMMUNE DISEASE USING ALLOGENIC T-CELLS | 2017 |
|
RU2773831C2 |
| COMPOSITIONS AND METHODS FOR PRODUCING T-CELLS | 2018 |
|
RU2793344C2 |
| COMPOSITIONS AND METHODS USED FOR ASSESSING CYTOTOXICITY OF SINGLE CELLS | 2009 |
|
RU2532228C2 |
| YEAST-BASED IMMUNOTHERAPEUTIC COMPOSITIONS WITH BRACHYURY | 2012 |
|
RU2690180C2 |
| METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE | 2019 |
|
RU2800920C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| IMMUNOTHERAPEUTIC COMPOSITIONS BASED ON YEAST WITH BRACHYURY | 2012 |
|
RU2619850C2 |
| VACCINATIVE TUMOR VACCINE COMPOSITION | 2008 |
|
RU2682726C2 |
| METHODS OF MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA TREATMENT BY T-CELL THERAPY | 2016 |
|
RU2743381C2 |
